# OnCo record nct02210104 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct02210104/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct02210104", "NCT02210104" ;
  schema:name "Autologous CD4+ NY-ESO-1-specific T cells with ipilimumab in NY-ESO-1-expressing tumours (MD Anderson phase 1, withdrawn)"@en ;
  schema:description "A planned MD Anderson trial of helper T cells against the NY-ESO-1 protein, given with the immunotherapy drug ipilimumab, for melanoma and sarcoma. It was withdrawn before anyone joined."@en ;
  schema:url <https://onco.cc/trials/nct02210104/> ;
  schema:dateModified "2026-11-05"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02210104> ;
  onco:status "withdrawn" ;
  onco:tag "failure" ;
  onco:phase "1" ;
  schema:startDate "2016-12" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/sarcoma/> ;
  onco:targets <https://onco.cc/targets/ctag1b/> ;
  onco:drugs <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/cyclophosphamide/> ;
  onco:institutions <https://onco.cc/institutions/md-anderson/>, <https://onco.cc/institutions/nci/> ;
  onco:terms <https://onco.cc/terms/endogenous-t-cell-therapy/> ;
  onco:people <https://onco.cc/people/cassian-yee/> .